A Study Of PF-04449913 Administered Alone In Select Solid Tumors

Plain-language summary

This study evaluates the drug PF-04449913 administered alone in patients with advanced/metastatic solid tumors. It included patients with confirmed advanced tumors and adequate organ function. It was a Phase 1 study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Pfizer

Intervention

PF-04449913

Start date

5/11/2011

Estimated completion

12/28/2012

Countries

United States

Related genes

Locations

• Los Angeles, United States
• Los Angeles, United States
• Los Angeles, United States
• Los Angeles, United States
• Aurora, United States
• Aurora, United States
• Aurora, United States
• Boston, United States
• Boston, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Histological or cytological diagnosis of advanced/metastatic solid tumor
* Adequate Bone Marrow Function
* Adequate Renal Function
* Adequate Liver Function

Exclusion Criteria:

* Patients with known symptomatic brain metastases requiring steroids
* Current active treatment on another clinical trial
* Major surgery or radiation therapy within 4-weeks of starting study treatment